跳至主要内容
临床试验/NCT02704572
NCT02704572已完成不适用

Comparison of Immune Response Induced by Zoster Vaccine According to the Timing of Vaccination After Zoster Illness

Seoul National University Hospital2 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2016年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Varicella-zoster virus-specific interferon-gamma ELISPOT response

研究概览

简要总结

The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patients aged over 50 with history of zoster within 5 years.

详细描述

Zoster vaccination is recommended by FDA for adults aged 60 years or older, and is approved for people aged 50 through 59 years old. For patients who had shingles, there is no specific length of time they must wait before receiving shingles vaccine. It is generally recommended that patients should wait for 6 to 12 months after recovery.

The investigators plan to make scientific recommendation for optimal timing of zoster vaccine after zoster illness by comparing immune response between two groups (vaccination at 6 months to 2 years after shingles vs. 2 to 5 years after shingles). Primary outcome is ELISPOT response at week 6 after vaccination. Secondary outcome is gpELISA titer at week 6 after vaccination.

All the patients will be asked if they have any contraindications for zoster vaccine by a physician before vaccination. And they will be monitored for any adverse reaction of the vaccination after 6 weeks (visiting the hospital).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults aged 50 years or older who have had shingles in 5 years
  • Adults who did not receive zoster vaccination yet
  • Adults who can understand and agreed with the informed consents.

排除标准

  • Adults who have conditions which is contraindication for zoster vaccine
  • Adults who had zoster vaccination already
  • Adults who take immunosuppressants
  • Human Immunodeficiency Virus (HIV) patients whose CD4 T cell counts below 500/mm3
  • Adults with autoimmune disease who are anticipated to have a problem with immunogenicity for vaccine
  • Adults who had organ transplantation and receive immunosuppressants
  • Adults who are suspected to have active infectious disease
  • Adults who are not eligible for zoster vaccination by investigator's assessment

结局指标

主要结局

Varicella-zoster virus-specific interferon-gamma ELISPOT response

时间窗: before Zostavax vaccination and at week 6 after vaccination

Investigators measure the number of SFC (spot forming cells) using interferon-gamma ELISPOT (enzyme-linked immunospot) assay at both right before vaccination and week 6 after vaccination and see the change between two values.

次要结局

  • Antibody titer against glycoprotein of varicella-zoster virus(before Zostavax vaccination and at week 6 after vaccination)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wan Beom Park

Associate Professor

Seoul National University Hospital

研究点 (2)

Loading locations...

相似试验